Harry J. Leonhardt
2016 - Halozyme Therapeutics
In 2016, Harry J. Leonhardt earned a total compensation of $1.6M as Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at Halozyme Therapeutics, a 44% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $204,000 |
|---|---|
| Option Awards | $500,013 |
| Salary | $405,000 |
| Stock Awards | $499,998 |
| Other | $10,762 |
| Total | $1,619,773 |
Leonhardt received $500K in option awards, accounting for 31% of the total pay in 2016.
Leonhardt also received $204K in non-equity incentive plan, $405K in salary, $500K in stock awards and $10.8K in other compensation.
Rankings
In 2016, Harry J. Leonhardt's compensation ranked 5,887th out of 14,075 executives tracked by ExecPay. In other words, Leonhardt earned more than 58.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,887 out of 14,075 | 58th |
Division Manufacturing | 2,131 out of 5,489 | 61st |
Major group Chemicals And Allied Products | 701 out of 1,895 | 63rd |
Industry group Drugs | 528 out of 1,538 | 66th |
Industry Biological Products, Except Diagnostic Substances | 97 out of 279 | 65th |
Source: SEC filing on March 24, 2017.
Leonhardt's colleagues
We found four more compensation records of executives who worked with Harry J. Leonhardt at Halozyme Therapeutics in 2016.
News
Poseida Therapeutics CEO Mark Gergen's 2022 pay jumps 55% to $4.4M
April 26, 2023
Poseida Therapeutics CEO Eric Ostertag's 2021 pay jumps 633% to $6.3M
April 27, 2022
Halozyme Therapeutics CEO Helen Torley's 2019 pay rises 1% to $5.9M
March 20, 2020
Halozyme Therapeutics CEO Helen Torley's 2018 pay rises 12% to $5.8M
March 22, 2019